Translational research describes the systematic transfer of findings from basic research into clinical application and vice versa. The objective is to develop scientific findings in such a way that diagnostic procedures, pharmaceuticals, medical devices, or treatment strategies emerge that actually reach patients. The process is often described as “bench to bedside” and “bedside to bench,” i.e., in both directions.
In drug development, translational research is particularly important for bridging the gap between preclinical models and clinical endpoints. This includes biomarker strategies, dose finding, patient selection, and mechanism-based hypotheses. For medical devices, such as digital health applications, translational approaches can also help define relevant clinical evidence of benefit and appropriate populations. This has direct consequences for sponsors and CROs: sample logistics, laboratory partners, data flows, and reporting must be considered early on to ensure that the data generated are later suitable for regulatory purposes.
Objectives and Typical Questions
Typical objectives include the identification of mechanisms of action, the selection of appropriate target populations, the development of companion diagnostics, and the derivation of surrogate endpoints. Translational research aims to reduce uncertainties early, for example by linking preclinical data with early clinical signals. This can increase the probability that a program will be successful later in Phase II or III.
Common questions include: Which patient subgroups benefit? Which dose achieves a desired target effect? Which safety risks are plausible? Which biomarkers are suitable for monitoring or response? The answers influence study design, endpoint selection, and the planning of sample collections. It is important to clearly separate exploratory and confirmatory objectives to avoid overinterpretation and multiplicity issues. A sound plan therefore defines hypotheses, prioritization of biomarkers, and criteria for when a signal is considered robust.
Methods, Data Sources, and Integration into Clinical Development
Methodologically, translational work encompasses a broad spectrum: omics analyses (genomics, proteomics), imaging, pharmacokinetics and pharmacodynamics, modeling and simulation, as well as the integration of routine clinical data. In early studies, exploratory analyses are frequently conducted to generate hypotheses. For later registration studies, however, biomarkers and assays must be analytically validated and clinically qualified. In practice, this includes specifications for sample matrix, stability, measurement range, precision, and handling of batch effects.
Translational research directly impacts the clinical development program. In Phase I studies, pharmacodynamic biomarkers can be used to demonstrate proof of mechanism. In Phase II studies, biomarkers and adaptive designs help optimize dose and population. In Phase III studies, translational endpoints must be clearly distinguished from primary efficacy endpoints to ensure unambiguous regulatory assessment. In practical terms, this means: a translational plan defines which samples are collected when, how they are analyzed, which data feed into which evaluations, and how changes are versioned.
Another important aspect is data integration. Translational data are often high-dimensional and generated in different systems (laboratory LIMS, imaging platforms, EDC, ePRO). To enable later analyses, metadata, data standards, and unique identifiers should be defined early. This reduces the risk that samples are available but can no longer be unambiguously assigned to a visit or therapeutic exposure.
Operational Implementation: Sample Logistics, Data Quality, Best Practices
A central role is played by the quality of sample and data logistics: biobanking, chain of custody, standardized preanalytics, and documented laboratory processes. For clinical trials, requirements for essential documents, audit trail, and data integrity must be considered early. In multicenter studies, harmonized processes, training, and clear responsibilities are critical to ensure that samples are correctly collected, labeled, transported, and analyzed.
Typical risks include assay changes during a program, inconsistent SOPs between laboratories, or incomplete metadata (e.g., collection time, storage conditions). Best practices include clear governance (roles between sponsor, CRO, and laboratory), quality-assured data transfer (e.g., structured laboratory data formats), and integrated reporting that consistently combines translational and clinical results. Data protection and purpose limitation must also be considered, particularly for genetic analyses or secondary use of samples. In operational audits, it is therefore frequently checked whether sample pathways and data transfers are fully documented and whether analyses are available in time for go/no-go decisions.
Best practices from experience also include: an early-defined list of “critical samples” (e.g., baseline and early on-treatment time points), clear escalation pathways for cold chain deviations, and monitoring of sample completeness similar to the clinical dataset. This helps avoid situations where biomarker analysis later fails due to systematic gaps.
Regulatory and Ethical Aspects
Translational research touches on regulatory and ethical requirements. For clinical trials under EU Regulation 536/2014, consent processes, sample use, and data processing must be transparently described. Biosamples may be assessed as part of the study or as a separate research component depending on the context, which influences ethics opinions and documentation obligations.
When translational analyses are included in registration dossiers, authorities expect comprehensible validation data and clear interpretation. For companion diagnostics or in vitro diagnostics, additional requirements of IVDR 2017/746 are relevant. For medical devices, MDR 2017/745 may be applicable if biomarker-based subgroup analyses are included in the clinical evaluation. Overall, results must be reproducible, auditable, and methodologically sound, including traceable versioning of analysis code and laboratory procedures.
FAQ
What is the difference between translational and clinical research?
Clinical research tests interventions in humans and focuses on efficacy and safety. Translational research connects preclinical findings with clinical data to understand mechanisms and make clinical development more efficient.
Why are biomarkers so important in translational research?
Biomarkers help make mechanisms measurable, identify patient subgroups, and detect early efficacy signals. For regulatory decisions, however, they must be measured in a valid, comprehensible, and consistent manner.
What role does consent play for biosamples?
Informed consent must cover purpose, scope, storage, possible secondary use, and data protection. In Europe, these aspects are frequently reviewed together with ethics committees.
Regulatory References (Selection)
- Regulation (EU) No. 536/2014 (Clinical Trials Regulation)
- ICH E6(R3): Good Clinical Practice
- EU IVDR 2017/746 (for companion diagnostics/in vitro diagnostics)